期刊文献+

含钆MR对比剂与肾源性系统性纤维化的关系 被引量:7

The relationship of nephrogenic systemic fibrosis with exposure to gadolinium contrast agents
下载PDF
导出
摘要 肾源性系统性纤维化(Nephrogenicsy stemic fibrosis,NSF)是近年才发现的一种仅发生于肾病患者的全身性疾病。NSF最初于1997年在美国南加利福尼亚的。肾移植中心发现,于2000年由Cowper等报道,称为“透析引起的硬化性黏液水肿样皮肤病”,2001年又对其临床和组织学特点进行了描述,将其命名为肾源性纤维化性皮肤病(NFD),
出处 《中国临床医学影像杂志》 CAS 北大核心 2009年第1期53-54,共2页 Journal of China Clinic Medical Imaging
  • 相关文献

参考文献11

  • 1Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema like cutaneous diseases in renal-dialysis patients [J]. Lancet, 2000, 356: 1000-1001.
  • 2Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy(Review)[J]. Am J Dermatopathol, 2001, 23: 383-393.
  • 3Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy(Review)[J]. Am J Kidney Dis, 2005, 46: 763-765.
  • 4Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [J]. Nephrol Dial Transplant, 2006, 21: 1104-1108.
  • 5Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging [J]. J Am Soc Nephrol, 2006, 17: 2359-2362.
  • 6High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis[J]. J Am Acad Dermatol, 2007, 56: 21-26.
  • 7Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy [J]. J Am Acad Dermatol, 2007, 56: 27-30.
  • 8Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents: St.Louis, Missouri, 2002-2006[J]. MMWR, 2007, 56: 137-141.
  • 9Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation[J]. Radiology, 2007, 243: 148-157.
  • 10Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concermed[J]. AJR, 2007, 188: 586-592.

同被引文献57

  • 1王翠艳,赵斌,王光彬,张增芳,邱秀玲.三维增强MR血管成像在周围型动脉闭塞症分级中的应用价值[J].中华放射学杂志,2007,41(6):598-601. 被引量:11
  • 2Reed PS,Dixon SR,Boura JA,et al.Comparison of the usefulness of Gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography.Am J Cardiol,2007,100:1090-1093.
  • 3Sam AD,Morasch SD,Collins J,et al.Safety and gadolinium contrast angiography in patients with chronic renal insufficiency.J Vasc Surg,2003,38:313-318.
  • 4Runge VM.Safety of approved MR contrast media for intravenous injection.J Magn Reson Imaging,2000,12:205-213.
  • 5Grobner T.Gadolinium:a special trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis.Nephrol Dial Transplant,2006,21:1104-1108.
  • 6Marckmann P,Skov L,Rossen K,et al.Nephrogenic systemic fibrosis:suspected causative role of gadodiamide used for contrastenhanced magnetic resonance imagping.J Am Soc Nephrol,2006,17:2359-2362.
  • 7High WA,Ayers RA,Chandler J,et al.Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.J Am Acad Dermatol,2007,56:21-26.
  • 8Bryant BJ,Im K,Broome DR.Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.Clin Radiol,2009,64:706-713.
  • 9Levey AS,Coresh J,Balk E,et al.National Kidney Foundation practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Ann Intern Med,2003:137-147.
  • 10Ma YC,Zou L,Chen JH,et al.Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease.J Am Soc Nephrol,2006,17:2937-2944.

引证文献7

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部